Abstract | OBJECTIVE: METHODS: A retrospective chart review was conducted on patients treated at the Comprehensive Gynecologic Cancer Center between January 2014 and 2019. Based on the inclusion criteria, 24 eligible patients who received HIPEC ( paclitaxel 175 mg/m2, for 90 minutes, at 42°C) ( HIPEC group) as consolidation treatment after terminating the adjuvant chemotherapy were identified. Another 24 patients who met the inclusion criteria and did not receive HIPEC were matched, representing the non- HIPEC group. Disease-free survival (DFS) and overall survival (OS) were examined between the two groups. RESULTS: The median DFS was 28.7 and 24.2 months in the HIPEC and non- HIPEC groups, respectively (P=0.688). The 3-year DFS rates in the HIPEC and non-HPEC groups were 39.5% and 32.6%, respectively. However, the median OS was not determined. The 5-year OS rates in the HIPEC and non- HIPEC groups were 86.2% and 81.3%, respectively (P=0.850). One patient developed grade 3 neutropenia. Other patients experienced mild adverse events after HIPEC. CONCLUSION: This study suggests that consolidation HIPEC could not support the survival benefit after completing the first-line treatment for patients with advanced ovarian cancer, although no severe specific safety issues were found. Therefore, randomized trials evaluating consolidation HIPEC for the management of ovarian cancer are warranted.
|
Authors | Jieun Ko, Hyeong In Ha, Min Chul Choi, Sang Geun Jung, Hyun Park, Won Duk Joo, Seung Hun Song, Chan Lee, Joon Mo Lee |
Journal | Obstetrics & gynecology science
(Obstet Gynecol Sci)
Vol. 64
Issue 5
Pg. 437-443
(Sep 2021)
ISSN: 2287-8572 [Print] Korea (South) |
PMID | 34325503
(Publication Type: Journal Article)
|